Fate stock: buy or sell?
May 22nd, 2020
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Should I buy Fate stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, 2 buy setups match with Fate Therapeutics stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Fate stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for FATE stock for the last 30 days.
Fate stock analysis
After climbing to all-time highs several times in past weeks, Fate boosted 5.04% to $35.23.
After several days of continuous rises in past weeks, Fate boosted 5.04% to $35.23. On March FATE price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since last February when SMA100d and SMA200d crossed up, FATE price gained $5.87 per share (19.99%). On May 22nd, FATE hit a new all time high, pushing higher than on Thursday tops. Check different trading setups that use ATHs as triggers.
Fate Therapeutics shares climbed 23.83% this week and reached a new all time high at $35.25. Late April FATE collapsed a hair-raising -15.53% in just one week.
If you observe the weekly chart, price finally broke over the resistance at $32.00 and continued climbing. By mid February, SMA20w and SMA40w crossed up triggering a rise of 21.99%. Since early December 2019 when FATE stock price broke up the SMA40w line, it gained $21.56 (157.72%).
Fate stock price history
Fate stock went public on October 1st, 2013 with a price of $6.561. Since then, FATE stock surged a 437.00%, with an average of 72.80% per year. If you had invested $1,000 in Fate stock in 2013, it would worth $4,370.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Fate stock historical price chart
FATE stock reached all-time highs on May/22 with a price of $35.25.
Fate stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not found any price prediction for Fate Therapeutics stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Fate presented its financial report, posting a tiny gain for the Earnings per Share (EPS) ratio. Experts expected $-0.24 per share, but Fate posted $-0.25.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an amazing increase of 15.44% to $4.74 M USD. Instead, its income margin (compared to sales) collapsed to -1,405.02%, that is $-66.60 million.
|2013||$0.97 M||-||$-20.89 M-2151.4%||-|
|2015||$2.43 M||150.36%||$-29.99 M-1233.7%||43.57%|
|2016||$4.40 M||81.08%||$-33.46 M-760.2%||11.57%|
|2017||$4.11 M||-6.72%||$-42.95 M-1046.1%||28.36%|
|2018||$4.74 M||15.44%||$-66.60 M-1405.0%||55.05%|
Quarterly financial resultsFate Therapeutics reported $1.66 M in sales for 2018-Q4, a 61.89% up compared to previous quarter. Reported quarter income marked $-16.03 million with a profit margin of -964.90%. Profit margin rocketed a 670.77% compared to previous quarter when profit margin was -1,635.67%. When comparing sales to same quarter last year, Fate sales marked an astounding gain and skyrocketed a 61.73%.
|2017-Q1||$1.03 M||-||$-10.13 M-983.5%||-|
|2017-Q2||$1.03 M||0.00%||$-9.65 M-936.9%||-4.74%|
|2017-Q3||$1.03 M||0.00%||$-10.68 M-1036.9%||10.67%|
|2017-Q4||$1.03 M||-0.29%||$-12.50 M-1216.8%||17.01%|
|2018-Q1||$1.03 M||-0.10%||$-14.14 M-1377.7%||13.11%|
|2018-Q2||$1.03 M||0.10%||$-19.65 M-1913.7%||39.04%|
|2018-Q3||$1.03 M||-0.10%||$-16.78 M-1635.7%||-14.61%|
|2018-Q4||$1.66 M||61.89%||$-16.03 M-964.9%||-4.50%|
Fate ownershipChecking Fate Therapeutics ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Fate shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 2.07% of all shares.
Bearish positions for FATE stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Fate:
|Market cap||$2.7 B|
|Total shares||77.7 M|
|Float shares||65.4 M|
|- Institutional holdings (%)||94.7%|
|- Insider holdings (%)||2.1%|
|Shares in short selling||0.0%|
|Friday, May 22nd, 2020|
|Day range||$32.12 - $35.25|
|Average true range||$2.41|
|50d mov avg||$26.66|
|100d mov avg||$26.30|
|200d mov avg||$21.39|
Fate performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Fate Therapeutics against in the following table: